HRP20161402T1 - Kombinacije agonista serotoninskih receptora za liječenje poremećaja kretanja - Google Patents
Kombinacije agonista serotoninskih receptora za liječenje poremećaja kretanja Download PDFInfo
- Publication number
- HRP20161402T1 HRP20161402T1 HRP20161402TT HRP20161402T HRP20161402T1 HR P20161402 T1 HRP20161402 T1 HR P20161402T1 HR P20161402T T HRP20161402T T HR P20161402TT HR P20161402 T HRP20161402 T HR P20161402T HR P20161402 T1 HRP20161402 T1 HR P20161402T1
- Authority
- HR
- Croatia
- Prior art keywords
- parts
- use according
- compound
- pharmaceutical preparation
- pharmaceutically acceptable
- Prior art date
Links
- 208000016285 Movement disease Diseases 0.000 title claims 9
- 238000011282 treatment Methods 0.000 title claims 3
- 239000000952 serotonin receptor agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 239000000018 receptor agonist Substances 0.000 claims 7
- 229940044601 receptor agonist Drugs 0.000 claims 7
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims 6
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 4
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 claims 4
- 101150050738 HTR1B gene Proteins 0.000 claims 3
- 101150039275 Htr1f gene Proteins 0.000 claims 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims 3
- 229960002495 buspirone Drugs 0.000 claims 3
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 3
- 229960003638 dopamine Drugs 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 229960001360 zolmitriptan Drugs 0.000 claims 3
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 2
- 102000006378 Catechol O-methyltransferase Human genes 0.000 claims 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims 2
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 2
- 101100321769 Takifugu rubripes htr1d gene Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000000946 synaptic effect Effects 0.000 claims 2
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 claims 1
- 101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 claims 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 1
- BVMYCHKQPGEOSI-UHFFFAOYSA-N 8-[2-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)ethyl]-8-azaspiro[4.5]decane-7,9-dione Chemical compound C1C(=O)N(CCNCC2OC3=CC=CC=C3OC2)C(=O)CC21CCCC2 BVMYCHKQPGEOSI-UHFFFAOYSA-N 0.000 claims 1
- QYFHCFNBYQZGKW-BDQAORGHSA-N 8-[4-[[(3s)-5-methoxy-3,4-dihydro-2h-chromen-3-yl]-propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione;hydrochloride Chemical compound Cl.CCCN([C@H]1CC2=C(OC)C=CC=C2OC1)CCCCN(C(C1)=O)C(=O)CC21CCCC2 QYFHCFNBYQZGKW-BDQAORGHSA-N 0.000 claims 1
- 206010001541 Akinesia Diseases 0.000 claims 1
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010006100 Bradykinesia Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 102000018899 Glutamate Receptors Human genes 0.000 claims 1
- 108010027915 Glutamate Receptors Proteins 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000006083 Hypokinesia Diseases 0.000 claims 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 1
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 1
- 108010062431 Monoamine oxidase Proteins 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 206010044074 Torticollis Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229960002133 almotriptan Drugs 0.000 claims 1
- 229950000420 alnespirone Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- PKZXLMVXBZICTF-UHFFFAOYSA-N befiradol Chemical compound N1=CC(C)=CC=C1CNCC1(F)CCN(C(=O)C=2C=C(Cl)C(F)=CC=2)CC1 PKZXLMVXBZICTF-UHFFFAOYSA-N 0.000 claims 1
- 229950007200 befiradol Drugs 0.000 claims 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 1
- 229960000911 benserazide Drugs 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 229950005615 binospirone Drugs 0.000 claims 1
- 229960004205 carbidopa Drugs 0.000 claims 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical group NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000004206 drug-induced akathisia Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 229960002472 eletriptan Drugs 0.000 claims 1
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 claims 1
- 229960003337 entacapone Drugs 0.000 claims 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 claims 1
- 229960002053 flibanserin Drugs 0.000 claims 1
- 229960002284 frovatriptan Drugs 0.000 claims 1
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 229960000647 gepirone Drugs 0.000 claims 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 claims 1
- 208000036260 idiopathic disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229950003599 ipsapirone Drugs 0.000 claims 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 229960005254 naratriptan Drugs 0.000 claims 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 229950004193 perospirone Drugs 0.000 claims 1
- GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 claims 1
- 238000011458 pharmacological treatment Methods 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- YGYBFMRFXNDIPO-QGZVFWFLSA-N repinotan Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCNC[C@@H]1OC2=CC=CC=C2CC1 YGYBFMRFXNDIPO-QGZVFWFLSA-N 0.000 claims 1
- 229950009693 repinotan Drugs 0.000 claims 1
- 229960000425 rizatriptan Drugs 0.000 claims 1
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims 1
- HKFMQJUJWSFOLY-OAQYLSRUSA-N sarizotan Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CNC[C@@H]2OC3=CC=CC=C3CC2)=C1 HKFMQJUJWSFOLY-OAQYLSRUSA-N 0.000 claims 1
- 229950007903 sarizotan Drugs 0.000 claims 1
- 229960003708 sumatriptan Drugs 0.000 claims 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims 1
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 claims 1
- 229950000505 tandospirone Drugs 0.000 claims 1
- 229960004603 tolcapone Drugs 0.000 claims 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical group C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims 1
- 108020001588 κ-opioid receptors Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Farmaceutski pripravak ili set dijelova koji obuhvaća barem jedan spoj, gdje je taj spoj agonist receptora 5-HT1 D, 5-HT1 B i 5-HT1 F, ili njegov farmaceutski prikladan derivat,
gdje je taj spoj triptan, ili njegov farmaceutski prikladan derivat, i gdje taj pripravak ili set dijelova dalje obuhvaća agonist receptora 5-HT1 A, ili njegov farmaceutski prikladan derivat,
za uporabu u liječenju, prevenciji ili ublažavanju poremećaja kretanja.
2. Farmaceutski pripravak ili set dijelova za uporabu prema zahtjevu 1, gdje spoj ima veći afinitet i/ili učinkovitost aktivacije receptora za 5-HT1 D receptor nego za 5-HT1 B i 5-HT1 F receptore.
3. Farmaceutski pripravak ili set dijelova za uporabu prema bilo kojem od prethodnih zahtjeva, gdje se spoj odabire iz skupine koju čine zolmitriptan, sumatriptan, rizatriptan, naratriptan, almotriptan, frovatriptan i eletriptan, ili njihovi farmaceutski prikladni derivati.
4. Farmaceutski pripravak ili set dijelova za uporabu prema bilo kojem od prethodnih zahtjeva, gdje se agonist 5-HT1A receptora odabire iz skupine koju čine buspiron, alnespiron, binospiron, gepiron, ipsapiron, perospiron, tandospiron, befiradol, repinotan piklozotan, osemozotan, flesinoksan, flibanserin i sarizotan, ili njihovi farmaceutski prikladni derivati.
5. Farmaceutski pripravak ili set dijelova za uporabu prema bilo kojem od prethodnih zahtjeva, gdje je spoj zolmitriptan ili njegov farmaceutski prikladan derivat, i agonist 5-HT1A receptora je buspiron ili njegov farmaceutski prikladan derivat.
6. Farmaceutski pripravak ili set dijelova za uporabu prema bilo kojem od prethodnih zahtjeva, gdje se spoj primjenjuje u dozama od 0.05 - 200 mg/dan, na primjer u dozama od 0.5 - 60 mg/dan, na primjer u dozama od 0.5 – 10 mg/dan i agonist 5-HT1 A receptora se primjenjuje u dozama od 0.05 - 500 mg/dan, na primjer od 0.5 - 100 mg/dan, na primjer u dozama od 0.5 - 30 mg/dan.
7. Farmaceutski pripravak ili set dijelova za uporabu prema bilo kojem od prethodnih zahtjeva, dalje obuhvaća jednu ili više dodatnih djelatnih tvari.
8. Farmaceutski pripravak ili set dijelova za uporabu prema zahtjevu 7, gdje se navedena jedna ili više dodatnih djelatnih tvari odabire iz skupine koju čine: tvari koje povećavaju koncentraciju dopamina u sinaptičkoj pukotini; tvari koje se koriste za liječenje Parkinsonove bolesti; dopamin; L-DOPA; agonisti dopaminskih receptora ili njihovi farmaceutski prikladni derivati; inhibitori dekarboksilaze; COMT (katehol-O-metiltransferaza) inhibitori; NMDA (N-metil-D-aspartat) antagonisti; MAO-B inhibitori; modulatori serotoninskih receptora; agonisti kapa opioidnih receptora, GABA (gama-aminobutirična kiselina) modulatori, modulatori neuronskih kalijevih kanala i modulatori glutamat receptora.
9. Farmaceutski pripravak ili set dijelova za uporabu prema bilo kojem od zahtjeva 7 i 8, gdje je spoj zolmitriptan ili njegov farmaceutski prikladan derivat, agonist 5-HT1A receptora je buspiron ili njegov farmaceutski prikladan derivat, i jedna ili više dodatnih djelatnih tvari obuhvaća L-DOPA ili njegov farmaceutski prikladan derivat i/ili inhibitor dekarboksilaze /ili COMT inhibitor.
10. Farmaceutski pripravak ili set dijelova za uporabu prema zahtjevu 9, gdje je inhibitor dekarboksilaze karbidopa ili benzerazid; i/ili gdje je COMT inhibitor tolkapon ili entakapon.
11. Farmaceutski pripravak ili set dijelova za uporabu prema bilo kojem od prethodnih zahtjeva, gdje se poremećaj kretanja odabire iz skupine koju čine: poremećaj kretanja povezan s izmijenjenim ili poremećenim sinaptičkim razinama dopamina; Parkinsonova bolest; poremećaj kretanja povezan s Parkinsonovom bolešću, uključujući bradikineziju, akineziju i diskineziju; L-DOPA inducirana diskinezija; tardivna diskinezija i akatizija.
12. Farmaceutski pripravak ili set dijelova za uporabu prema bilo kojem od prethodnih zahtjeva, gdje se poremećaj kretanja odabire iz skupine koju čine ataksija, distonija, esencijalni tremor, Huntingtonova bolest, mioklonus, Rettov sindrom, Touretteov sindrom, Wilsonova bolest, korea, Machado-Josephova bolest, sindrom nemirnih nogu, spazmodički tortikolis, geniospazam, i poremećaj kretanja uzrokovan idiopatskom bolešću, genetičkom disfunkcijom ili infekcijama ili disfunkcijom bazalnih ganglija.
13. Farmaceutski pripravak ili set dijelova za uporabu prema bilo kojem od prethodnih zahtjeva, gdje je poremećaj kretanja uzrokovan ili povezan s farmakološkim liječenjem uključujući neuroleptičke lijekove, antipsihotike, antidepresive i antiemetike; ili uzrokovan ili povezan s prekidom uzimanja tvari uključujući opioide, barbiturate, kokain, benzodiazepine, alkohol i amfetamin.
14. Farmaceutski pripravak ili set dijelova za uporabu prema bilo kojem od zahtjeva 7 do 10, gdje se jedna ili više dodatnih djelatnih tvari primjenjuje istodobno, uzastopce ili odvojeno od farmaceutskog pripravka ili seta dijelova.
15. Uporaba farmaceutskog pripravka ili seta dijelova koji obuhvaća barem jedan spoj, gdje je taj spoj agonist receptora 5-HT1 D, 5-HT1 B i 5-HT1 F, ili njegov farmaceutski prikladan derivat, gdje je taj spoj triptan, ili njegov farmaceutski prikladan derivat, i gdje taj pripravak ili set dijelova dalje obuhvaća agonist receptora 5-HT1 A, ili njegov farmaceutski prikladan derivat, za proizvodnju lijeka za liječenje, prevenciju ili ublažavanje poremećaja kretanja.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39354510P | 2010-10-15 | 2010-10-15 | |
| DKPA201070441 | 2010-10-15 | ||
| US201161491945P | 2011-06-01 | 2011-06-01 | |
| EP11776071.0A EP2627328B1 (en) | 2010-10-15 | 2011-10-13 | Combinations of serotonin receptor agonists for treatment of movement disorders |
| PCT/DK2011/050383 WO2012048710A1 (en) | 2010-10-15 | 2011-10-13 | Combinations of serotonin receptor agonists for treatment of movement disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161402T1 true HRP20161402T1 (hr) | 2016-12-30 |
Family
ID=44883032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161402TT HRP20161402T1 (hr) | 2010-10-15 | 2016-10-26 | Kombinacije agonista serotoninskih receptora za liječenje poremećaja kretanja |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9186359B2 (hr) |
| EP (1) | EP2627328B1 (hr) |
| JP (1) | JP5907975B2 (hr) |
| KR (1) | KR101825972B1 (hr) |
| CN (2) | CN103402514B (hr) |
| AU (1) | AU2011316225B2 (hr) |
| BR (1) | BR112013009004B1 (hr) |
| CA (1) | CA2813648C (hr) |
| CY (1) | CY1118314T1 (hr) |
| DK (1) | DK2627328T3 (hr) |
| ES (1) | ES2602973T3 (hr) |
| HR (1) | HRP20161402T1 (hr) |
| HU (1) | HUE031661T2 (hr) |
| IL (1) | IL225758A (hr) |
| LT (1) | LT2627328T (hr) |
| MX (1) | MX353625B (hr) |
| PL (1) | PL2627328T3 (hr) |
| PT (1) | PT2627328T (hr) |
| RS (1) | RS55332B1 (hr) |
| RU (1) | RU2611376C2 (hr) |
| SI (1) | SI2627328T1 (hr) |
| WO (1) | WO2012048710A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012163365A1 (en) * | 2011-06-01 | 2012-12-06 | Concit Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
| EP2838517B1 (en) * | 2012-04-18 | 2017-10-18 | Contera Pharma APS | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
| WO2013188210A2 (en) * | 2012-06-11 | 2013-12-19 | Psychogenics, Inc. | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments |
| US11478476B2 (en) | 2014-06-26 | 2022-10-25 | Contera Pharma Aps | Use of buspirone metabolites |
| DK3131549T3 (en) * | 2014-07-09 | 2018-05-28 | Pf Medicament | PROCEDURE FOR TREATING MOVEMENT DISORDERS WITH BEFIRADOL |
| WO2016210431A1 (en) * | 2015-06-26 | 2016-12-29 | Wright State University | Method of treating sepsis-induced myopathy |
| US11013830B2 (en) * | 2015-11-20 | 2021-05-25 | Institut Pasteur | 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential |
| CN109689036A (zh) | 2016-07-11 | 2019-04-26 | 康特拉医药公司 | 用于治疗早晨运动不能的脉冲药物输送系统 |
| WO2020127954A1 (en) | 2018-12-20 | 2020-06-25 | Contera Pharma Aps | Treatment of movement disorders |
| WO2021127391A1 (en) * | 2019-12-20 | 2021-06-24 | The Jackson Laboratory | Molecular targets for addiction |
| CN112931397B (zh) * | 2021-01-25 | 2024-02-27 | 江南大学 | 一种帕金森病动物模型的构建方法 |
| CN114712365B (zh) * | 2022-06-07 | 2022-08-23 | 山东绿叶制药有限公司 | Trk抑制剂在制备治疗迟发性运动障碍药物中的应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759371A (fr) | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
| US3976776A (en) | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4182763A (en) | 1978-05-22 | 1980-01-08 | Mead Johnson & Company | Buspirone anti-anxiety method |
| US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4438119A (en) | 1982-12-23 | 1984-03-20 | Mead Johnson & Company | Method for alleviation of extrapyramidal motor disorders |
| US4640921A (en) | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
| US4687772A (en) | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
| US4777173A (en) | 1987-03-25 | 1988-10-11 | Bristol-Myers Company | Method for treatment of alcohol abuse |
| US5185329A (en) | 1988-08-30 | 1993-02-09 | Bristol-Myers Squibb Company | Method for treatment of substance addiction |
| US6432956B1 (en) | 1990-02-12 | 2002-08-13 | William C. Dement | Method for treatment of sleep apneas |
| ATE156823T1 (de) | 1990-06-07 | 1997-08-15 | Zeneca Ltd | Therapeutische heterocyclische verbindungen |
| US5633009A (en) | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
| US5431922A (en) | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
| GB9209882D0 (en) | 1992-05-07 | 1992-06-24 | Glaxo Lab Sa | Compositions |
| US5484788A (en) | 1993-03-26 | 1996-01-16 | Beth Israel Hospital Association | Buspirone as a systemic immunosuppressant |
| US5637314A (en) | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
| GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
| US6150365A (en) | 1999-08-05 | 2000-11-21 | Bristol-Myers Squibb Company | Anxiety method |
| GB9928578D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Pharmaceutical formulations |
| AU2002230411A1 (en) * | 2000-11-29 | 2002-06-11 | Eli Lilly And Company | 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence |
| WO2002053139A2 (en) * | 2001-01-05 | 2002-07-11 | Eli Lilly And Company | Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders |
| US8329734B2 (en) | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
| US20040235920A1 (en) * | 2001-09-12 | 2004-11-25 | Gerd Bartoszyk | Novel use of substituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders |
| DE10353657A1 (de) * | 2003-11-17 | 2005-06-23 | Merck Patent Gmbh | Indolderivate |
| WO2005075467A2 (en) | 2004-02-06 | 2005-08-18 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of zolmitriptan |
| MX2007002790A (es) * | 2004-09-07 | 2007-04-23 | Pfizer | Combinacion de un agonista del receptor 5-hidroxitriptamina (i) y un ligando alfa-2-delta para el tratamiento de migrana. |
| US9066903B2 (en) | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| EA014576B1 (ru) * | 2006-06-16 | 2010-12-30 | Солвей Фармасьютикалс Б.В. | Комбинированные препараты, содержащие бифепрунокс и l-допу |
| TW200831479A (en) * | 2006-09-26 | 2008-08-01 | Cytrx Corp | Pharmaceutical compositions and methods for treating diseases |
| WO2008047839A1 (fr) * | 2006-10-19 | 2008-04-24 | Dainippon Sumitomo Pharma Co., Ltd. | Agoniste du récepteur de la 5-ht1a |
| WO2008115797A1 (en) * | 2007-03-16 | 2008-09-25 | Pavo, Inc. | Therapeutic compositions and methods |
| JP5269894B2 (ja) | 2007-06-27 | 2013-08-21 | ハンミ ファーム． シーオー．， エルティーディー． | 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置 |
| EP2317996A1 (en) | 2008-06-24 | 2011-05-11 | Anders Björklund | Eltoprazine for suppression of l-dopa induced dyskinesias |
| MX2011003984A (es) | 2008-10-14 | 2011-05-10 | Mcneil Ab | Forma de dosis intraoral de multiples porciones y uso de esta. |
| BRPI1006902A2 (pt) | 2009-01-23 | 2016-02-16 | Aziende Chimiche Riunte Angelini Francesco A C R A F S P A | formulação farmacêutica ou alimentícia de liberação controlada, processo para a produção de uma forma farmacêutica ou alimentícia, sistema de liberação controlada, e, uso de um sistema de liberação controlada |
| SG181896A1 (en) | 2009-12-23 | 2012-07-30 | Map Pharmaceuticals Inc | Novel ergoline analogs |
| WO2012163365A1 (en) | 2011-06-01 | 2012-12-06 | Concit Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
-
2011
- 2011-10-13 CN CN201180060726.9A patent/CN103402514B/zh active Active
- 2011-10-13 AU AU2011316225A patent/AU2011316225B2/en active Active
- 2011-10-13 BR BR112013009004-9A patent/BR112013009004B1/pt active IP Right Grant
- 2011-10-13 PT PT117760710T patent/PT2627328T/pt unknown
- 2011-10-13 CN CN201510595196.8A patent/CN105193809B/zh active Active
- 2011-10-13 US US13/879,128 patent/US9186359B2/en active Active
- 2011-10-13 PL PL11776071T patent/PL2627328T3/pl unknown
- 2011-10-13 LT LTEP11776071.0T patent/LT2627328T/lt unknown
- 2011-10-13 DK DK11776071.0T patent/DK2627328T3/en active
- 2011-10-13 JP JP2013533090A patent/JP5907975B2/ja active Active
- 2011-10-13 CA CA2813648A patent/CA2813648C/en active Active
- 2011-10-13 RU RU2013120481A patent/RU2611376C2/ru active
- 2011-10-13 EP EP11776071.0A patent/EP2627328B1/en active Active
- 2011-10-13 HU HUE11776071A patent/HUE031661T2/en unknown
- 2011-10-13 SI SI201131000A patent/SI2627328T1/sl unknown
- 2011-10-13 MX MX2013004067A patent/MX353625B/es active IP Right Grant
- 2011-10-13 RS RS20160985A patent/RS55332B1/sr unknown
- 2011-10-13 ES ES11776071.0T patent/ES2602973T3/es active Active
- 2011-10-13 KR KR1020137012486A patent/KR101825972B1/ko active IP Right Grant
- 2011-10-13 WO PCT/DK2011/050383 patent/WO2012048710A1/en active Application Filing
-
2013
- 2013-04-14 IL IL225758A patent/IL225758A/en active IP Right Grant
-
2015
- 2015-11-10 US US14/937,286 patent/US10632116B2/en active Active
-
2016
- 2016-10-26 HR HRP20161402TT patent/HRP20161402T1/hr unknown
- 2016-11-14 CY CY20161101164T patent/CY1118314T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161402T1 (hr) | Kombinacije agonista serotoninskih receptora za liječenje poremećaja kretanja | |
| Muñoz et al. | Serotonin neuron-dependent and-independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model | |
| JP2013539767A5 (hr) | ||
| Coccurello et al. | Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats | |
| RU2014145944A (ru) | Пероральная фармацевтическая композиция, подходящая для повышения эффективности лечения двигательных нарушений | |
| Munoz et al. | Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia | |
| HRP20161039T1 (hr) | Deuterirani derivati kateholamina i lijekovi koji sadrže navedene spojeve | |
| Jenner et al. | Adenosine, adenosine A2A antagonists, and Parkinson's disease | |
| Fajardo et al. | Disease-modifying therapies for osteoarthritis: current status | |
| HRP20231716T1 (hr) | Pripravci inhibitora dopa dekarboksilaze | |
| CY1120005T1 (el) | Συνεχης χορηγηση αναστολεων l-ντοπα, αποκαρβοξυλασης ντοπα, αναστολεων κατεχολ-ο-μεθυλ τρανσφερασης και συνθεσεις αυτων | |
| BRPI0409250B8 (pt) | Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar | |
| PA8815501A1 (es) | Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa | |
| AR066420A1 (es) | Composicion farmaceutica suministrable oronasofaringeamente para la prevencion alivio / y o tratamiento de trastornos de miembros inquietos. uso. | |
| Zhang et al. | NMDA GluN2B receptors involved in the antidepressant effects of curcumin in the forced swim test | |
| RS52457B (en) | POWDER FORMULATION FOR VALGANCICLOVIR | |
| HRP20160108T1 (hr) | Uporaba testosterona i 5-ht1a agonista u tretiranju seksualne disfunkcije | |
| BR112016029750A2 (pt) | dosagem intermitente de inibidor mdm2 | |
| RU2019116422A (ru) | Фармацевтическое применение композиции пролонгированного действия, содержащей пирфенидон, для лечения и обращения течения стеатогепатита человека (nafld/nash) | |
| BR112014013757A2 (pt) | método para tratar osteoartrite; método para tratar uma condição que envolve condrócitos funcionais insuficientes ou tecido cartilaginoso funcional insuficiente; e uso de um peptídeo | |
| US20170128446A1 (en) | Use of buspirone metabolites | |
| ES2555387T3 (es) | Uso de una combinación de ácidos D-aspártico y L-aspártico o sus sales para el tratamiento de la esterilidad masculina | |
| Jung et al. | Metabolomic analysis of sulfur-containing substances and polyamines in regenerating rat liver | |
| Cialdai et al. | Comparison between oral and intra-articular antinociceptive effect of dexketoprofen and tramadol combination in monosodium iodoacetate-induced osteoarthritis in rats | |
| Miranda et al. | Interaction between dexibuprofen and dexketoprofen in the orofacial formalin test in mice |